Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

Affiliations

Ricardo D. Parrondo: Department of Hematology-Oncology, Mayo Clinic Cancer Center
Betsy R. LaPlant: Quantitative Health Sciences, Mayo Clinic
Jamie Elliott: Department of Hematology-Oncology, Mayo Clinic Cancer Center
Andre Fernandez: Department of Hematology-Oncology, Mayo Clinic Cancer Center
Caitlin J. Flott: Department of Hematology-Oncology, Mayo Clinic Cancer Center
Diedre Arrington: Department of Hematology-Oncology, Mayo Clinic Cancer Center
Dustin Chapin: Department of Hematology-Oncology, Mayo Clinic Cancer Center
Jade Brown: Department of Hematology-Oncology, Mayo Clinic Cancer Center
Saurav Das: Department of Hematology-Oncology, Mayo Clinic Cancer Center
Vivek Roy: Department of Hematology-Oncology, Mayo Clinic Cancer Center
Asher A. Chanan-Khan: Department of Hematology-Oncology, Mayo Clinic Cancer Center
Sikander Ailawadhi: Department of Hematology-Oncology, Mayo Clinic Cancer Center

Abstract

No abstracts available.

ISSN: 2044-5385 (Online)
Publisher: Nature Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.nature.com/bcj/index.html